Ppl understandably bring up concerns on a population level with expanding screening in men >70yo.
Let us dive into data on this. I agree with @VickersBiostats we should always do 'risk stratified' screening whether >70 or <70yo (we should not be doing PSA screening in a 50 yo with a terminal condition with <1yr to live).
@ASTRO_org@ASCO@PCF_Science
X-torial: Cleaning up the misinformation about @JoeBiden and #ProstateCancer that I am reading everywhere.
The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA @NCCN PCa guidelines, hold leadership in @NRGonc@theNCI@US_FDA and dedicated my career to help men and their families suffering from PCa
@nytimes@WSJ@FoxNews@CNN@NBCNews@Reuters@ASCO@PCFnews @DeptofDefense
Valiant effort @UFalagario to revisit the question of BCR definition comparability for RP vs. RT for #prostatecancer. Closest seems to be nadir + 0.5 for RT vs. >0.5 with PSADT <9mos for RP.
I still personally want CSM outcomes for CER studies, but this is very helpful. #AUA25
Stockholm3 demonstrated the ability to reduce unnecessary biopsies compared with PSA across a multiethnic cohort of patients, according to data from the SEPTA trial. @HVigneswaran#pcsm#urology
https://t.co/IJq0xhu1iY
Stockholm3 in a Multiethnic Cohort for Prostate Cancer Detection (SEPTA) out on @JCO_ASCO
https://t.co/aIRD8uh4YH
The study aimed to assess the effectiveness of the Stockholm3 🇸🇪test in improving prostate cancer detection in a diverse cohort, including Asian, Black, Hispanic, and White men, who are typically underrepresented in clinical trials
Conducted as an observational, prospective multicenter trial, it included 2,129 participants with suspected #ProstateCancer .
➡️The primary objectives were to evaluate the noninferior sensitivity of Stockholm3 compared to prostate-specific antigen (PSA) levels and to demonstrate superior specificity in reducing unnecessary biopsies.
➡️The findings showed that Stockholm3 had comparable sensitivity to PSA in detecting clinically significant prostate cancer and significantly higher specificity, reducing benign and low-grade cancer biopsies by 45% overall.
The test performed consistently across all racial and ethnic groups, suggesting it as an effective tool for improving prostate cancer detection and reducing unnecessary procedures.
@HVigneswaran@TobiasNordstrom@RhubbBstat@Nptdot@michaelabern@uroegg@KaraWattsMD@lissmike@ALDCAbreu@geoffsonn@TPalsdotti
Henrik Grönberg, @karolinskainst
Adam B. Murphy
History repeats itself.......
Prostate Cancers in the Prostate-specific Antigen Interval of 1.8–3 ng/ml: Results from the Göteborg-2 Prostate Cancer Screening Trial - European Urology https://t.co/ZcQL0TVJiY
North American validation of STHLM3 in a large diverse cohort undergoing prostate biopsy; able to maintain relative sensitivity for GG2 and higher with far superior specificity (compared to PSA)